There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Vasodilator stress myocardial perfusion imaging (MPI) accounts for up to 50% of all
stress MPI studies performed in the U.S. In 2008, the Food and Drug Administration
approved regadenoson for stress testing in conjunction with MPI. Regadenoson, unlike
adenosine, is a selective A(2A) agonist that is given as an intravenous bolus at a
fixed dose, with less undesirable side effects including atrioventricular block and
bronchospasm. Unlike adenosine, regadenoson could be used in patients with mild-to-moderate
reactive airway disease. This review will summarize the pre-clinical and clinical
data on regadenoson, as they specifically relate to its use as a vasodilator stress
agent, currently the only approved selective A(2A) agonist.